MedTrace Logo

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02788513 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 611

Last updated 2020-11-06

Study results available
· View outcomes & findings →

Summary

The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

BI 425809 dose 1

DRUG

BI 425809 dose 2

DRUG

BI 425809 dose 3

DRUG

BI 425809 dose 4

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-11
Primary Completion
2019-09-12
Completion
2019-10-11
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Japan
  • Norway
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788513 on ClinicalTrials.gov